Antiplatelet therapy effectively reduces plasma plasminogen activator inhibitor-1 levels.
Toshiyuki
T
Sakata
Kazuomi
K
Kario
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001241:Aspirin / Q000008:administration & dosage*; D002545:Brain Ischemia / Q000097:blood / Q000188:drug therapy*; D016022:Case-Control Studies; D000077144:Clopidogrel; D015536:Down-Regulation; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood*; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D020521:Stroke / Q000097:blood / Q000188:drug therapy*; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D013997:Time Factors; D016896:Treatment Outcome
D017395:Plasminogen Activator Inhibitor 1; D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin